1. Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma
by Young Ae Kim, Ja Min Byun, Keeho Park, Gi Hwan Bae, Dukhyoung Lee, Dong Sook Kim, Sung-Soo Yoon, and Youngil Koh
BloodAdv
Volume 1(24):
November 14, 2017
© 2017 by The American Society of Hematology

2. Young Ae Kim et al. Blood Adv 2017;1:2138-2146
© 2017 by The American Society of Hematology

3. OS and PFS of all patients.
OS and PFS of all patients. (A) OS of all patients treated at SNUH. (B) OS of all patients treated at SNUH according to first-line chemotherapy. (C) PFS of all patients treated at SNUH. (D) PFS of all patients treated at SNUH according to first-line chemotherapy. (E) OS of all patients enrolled in KCCR. (F) OS of all patients enrolled in KCCR according to first-line chemotherapy. (G) PFS of all patients enrolled in KCCR. (H) PFS of all patients enrolled in KCCR according to first-line chemotherapy.
Young Ae Kim et al. Blood Adv 2017;1:
© 2017 by The American Society of Hematology

4. Comparison of survival according to chemotherapy regimen among patients in group 1.
Comparison of survival according to chemotherapy regimen among patients in group 1. (A) OS between patients receiving CHOP vs those receiving augmented CHOP based on SNUH data. (B) PFS between patients receiving CHOP vs those receiving a CHOP-like regimen based on SNUH data. (C) OS between patients receiving CHOP vs those receiving a CHOP-like regimen based on KCCR data. (D) PFS between patients receiving CHOP vs those receiving a CHOP-like regimen based on KCCR data.
Young Ae Kim et al. Blood Adv 2017;1:
© 2017 by The American Society of Hematology

5. Effect of age on survival outcomes for patients.
Effect of age on survival outcomes for patients. (A) OS between etoposide users and nonusers among patients age <45 years old based on SNUH data. (B) PFS between etoposide users and nonusers among patients age <45 years based on SNUH data. (C) OS between etoposide users and nonusers among patients age ≥45 years based on SNUH data. (D) PFS between etoposide users and nonusers among patients age ≥45 years based on SNUH data. (E) OS between etoposide users and nonusers among patients age <45 years based on KCCR data. (F) PFS between etoposide users and nonusers among patients age <45 years based on KCCR data. (G) OS between etoposide users and nonusers among patients age ≥45 years based on KCCR data. (H) PFS between etoposide users and nonusers among patients age ≥45 years based on KCCR data.
Young Ae Kim et al. Blood Adv 2017;1:
© 2017 by The American Society of Hematology